<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    8555803
   </pmid>
   <datecreated>
    <year>
     1996
    </year>
    <month>
     02
    </month>
    <day>
     27
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1996
    </year>
    <month>
     02
    </month>
    <day>
     27
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2009
    </year>
    <month>
     11
    </month>
    <day>
     18
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0959-8138
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       311
      </volume>
      <issue>
       7020
      </issue>
      <pubdate>
       <year>
        1995
       </year>
       <month>
        Dec
       </month>
       <day>
        16
       </day>
      </pubdate>
     </journalissue>
     <title>
      BMJ (Clinical research ed.)
     </title>
     <isoabbreviation>
      BMJ
     </isoabbreviation>
    </journal>
    <articletitle>
     Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
    </articletitle>
    <pagination>
     <medlinepgn>
      1602-7
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To compare effectiveness of levodopa and levodopa combined with selegiline in treating early, mild Parkinson's disease.
     </abstracttext>
     <abstracttext label="DESIGN" nlmcategory="METHODS">
      Open, long term, prospective randomised trial.
     </abstracttext>
     <abstracttext label="SETTING" nlmcategory="METHODS">
      93 hospitals throughout United Kingdom.
     </abstracttext>
     <abstracttext label="SUBJECTS" nlmcategory="METHODS">
      520 patients with early Parkinson's disease who were not receiving dopaminergic treatment.
     </abstracttext>
     <abstracttext label="INTERVENTIONS" nlmcategory="METHODS">
      Treatment with levodopa and dopa decarboxylase inhibitor (arm 1) or levodopa and decarboxylase inhibitor in combination with selegiline (arm 2).
     </abstracttext>
     <abstracttext label="MAIN OUTCOME MEASURES" nlmcategory="METHODS">
      Assessments of serial disability, frequency and severity of adverse events, and deaths from all causes.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      After average of 5-6 years' follow up, mortality ratio in arm 2 compared with arm 1 was 1.57 (95% confidence interval 1.09 to 2.30), and difference in survival between the two arms was significant (log rank test, P = 0.015). Hazard ratio adjusted for age and sex was 1.49 (1.02 to 2.16), and after adjustment for other baseline factors it increased to 1.57 (1.07 to 2.31). Patients in arm 1 had slightly worse disability scores than those in arm 2, but differences were not significant. Functionally disabling peak dose dyskinesias and on/off fluctuations were more frequent in arm 2 than arm 1. During the trial the dose of levodopa required to produce optimum motor control steadily increased in arm 1 (median daily dose 375 mg at 1 year and 625 mg at 4 years), but median dose in arm 2 did not change (375 mg).
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      Levodopa in combination with selegiline seemed to confer no clinical benefit over levodopa alone in treating early, mild Parkinson's disease. Moreover mortality was significantly higher with combination treatment, casting doubts on its chronic use in Parkinson's disease.
     </abstracttext>
    </abstract>
    <affiliation>
     Parkinson's Disease Research Group of the United Kingdom, National Hospital for Neurology and Neurosurgery, London.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Lees
      </lastname>
      <forename>
       A J
      </forename>
      <initials>
       AJ
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Comparative Study
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     ENGLAND
    </country>
    <medlineta>
     BMJ
    </medlineta>
    <nlmuniqueid>
     8900488
    </nlmuniqueid>
    <issnlinking>
     0959-535X
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Antiparkinson Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Levodopa
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Monoamine Oxidase Inhibitors
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      14611-51-9
     </registrynumber>
     <nameofsubstance>
      Selegiline
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      25614-03-3
     </registrynumber>
     <nameofsubstance>
      Bromocriptine
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      322-35-0
     </registrynumber>
     <nameofsubstance>
      Benserazide
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="Cites">
     <refsource>
      J Nerv Ment Dis. 1961 Aug;133:143-7
     </refsource>
     <pmid version="1">
      13876261
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Neurol Neurosurg Psychiatry. 1994 Feb;57(2):217-20
     </refsource>
     <pmid version="1">
      8126510
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Ann Neurol. 1995 Jan;37(1):95-8
     </refsource>
     <pmid version="1">
      7818264
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Mov Disord. 1995 May;10(3):250-6
     </refsource>
     <pmid version="1">
      7651439
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Q J Med. 1980;49(195):283-93
     </refsource>
     <pmid version="1">
      7465763
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Neurology. 1967 May;17(5):427-42
     </refsource>
     <pmid version="1">
      6067254
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Mod Treat. 1968 Mar;5(2):257-82
     </refsource>
     <pmid version="1">
      5655944
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1976 Feb 7;1(7954):292-6
     </refsource>
     <pmid version="1">
      55599
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Neurology. 1986 Nov;36(11):1528-30
     </refsource>
     <pmid version="1">
      3762973
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745-52
     </refsource>
     <pmid version="1">
      2841426
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Neurosci Res. 1991 Dec;30(4):666-72
     </refsource>
     <pmid version="1">
      1686284
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Ann Neurol. 1989 Nov;26(5):689-90
     </refsource>
     <pmid version="1">
      2510589
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 1996 Mar 16;312(7032):703; author reply 704-5
     </refsource>
     <pmid version="1">
      8597747
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 1996 Mar 16;312(7032):702-3; author reply 704-5
     </refsource>
     <pmid version="1">
      8597746
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 1996 Mar 16;312(7032):702; author reply 704-5
     </refsource>
     <pmid version="1">
      8597744
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 1995 Dec 16;311(7020):1583-4
     </refsource>
     <pmid version="1">
      8555790
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 1997 Aug 9;315(7104):370
     </refsource>
     <pmid version="1">
      9270472
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 1996 Mar 16;312(7032):704; author reply 704-5
     </refsource>
     <pmid version="1">
      8597750
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 1996 Mar 16;312(7032):703-4; author reply 704-5
     </refsource>
     <pmid version="1">
      8597749
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 1996 Mar 16;312(7032):703; author reply 704-5
     </refsource>
     <pmid version="1">
      8597748
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 1996 Mar 16;312(7032):704-5
     </refsource>
     <pmid version="1">
      8597751
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 1996 Mar 16;312(7032):702; author reply 704-5
     </refsource>
     <pmid version="1">
      8597745
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Antiparkinson Agents
     </descriptorname>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Benserazide
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Bromocriptine
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Cause of Death
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Disability Evaluation
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Administration Schedule
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Therapy, Combination
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Follow-Up Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Levodopa
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Monoamine Oxidase Inhibitors
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Parkinson Disease
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="Y">
      mortality
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Proportional Hazards Models
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Prospective Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Selegiline
     </descriptorname>
     <qualifiername majortopicyn="N">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Time Factors
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Failure
     </descriptorname>
    </meshheading>
   </meshheadinglist>
   <otherid source="NLM">
    PMC2551499
   </otherid>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1995
     </year>
     <month>
      12
     </month>
     <day>
      16
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1995
     </year>
     <month>
      12
     </month>
     <day>
      16
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1995
     </year>
     <month>
      12
     </month>
     <day>
      16
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     8555803
    </articleid>
    <articleid idtype="pmc">
     PMC2551499
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

